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ABSTRACT
Objective: The choice between primary debulking surgery (PDS) and neoadjuvant 
chemotherapy (NAC) in advanced ovarian cancer remains controversial. We evaluated NAC 
use in our center before and after results from a randomized trial were published, with the 
aim to determine the impact of changes in the neoadjuvant strategy on survival in advanced-
stage ovarian cancer.
Methods: We retrospectively investigated the clinical course of 435 patients with ovarian, 
tubal, or peritoneal carcinoma (International Federation of Gynecology and Obstetrics 
[FIGO] stage III or IV). According to the period of treatment, we stratified patients into a 
control group (n=216; diagnosed between 2006 and 2010; 83.8% underwent PDS) and a study 
group (n=219; diagnosed between 2011 and 2014; 48.9% received NAC followed by interval 
debulking surgery [IDS]).
Results: There were no between-group differences in age, body mass index, histology 
findings, or tumor grade. Compared to patients in the control group, those in the study 
group were more likely to receive NAC followed by IDS as first-line treatment (48.9% vs. 
16.2%; p<0.001), cytoreductive surgery to no-residual disease (21.5% vs. 10.2%; p<0.001), or 
radical surgery (57.5% vs. 35.6%; p<0.001). However, there was no between-group difference 
in postoperative morbidity. Kaplan-Meier analysis showed no between-group differences in 
progression-free or overall survival (p=0.449 and 0.952, respectively).
Conclusion: NAC incorporation resulted in increased optimal cytoreduction rates although 
no significant differences in survival outcomes were noted. NAC is advantageous for patients 
with high perioperative morbidity or unresectable disease.
Keywords: Ovarian Neoplasms; Neoadjuvant Therapy; Debulking Surgical Procedure; 
Chemotherapy, Adjuvant
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INTRODUCTION
Ovarian cancer is the leading cause of death from gynecologic malignancy [1]. In Korea, 
ovarian cancer incidence and mortality rates have recently increased [2,3]. Primary debulking 
surgery (PDS) followed by platinum-based chemotherapy is currently the standard treatment 
for advanced-stage ovarian cancer [4]. Recently, several randomized clinical trials have shown 
that neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS) is not 
inferior to PDS with respect to survival, postoperative morbidity, and mortality in women 
with stage III or IV ovarian cancer [5-8]. Therefore, NAC followed by IDS is considered a 
feasible alternative approach in advanced-stage ovarian cancer [9].
To date, few studies have examined the impact of the increased adoption of NAC as a primary 
treatment for advanced-stage ovarian cancer in clinical practice, where the choice between 
PDS and NAC remains controversial. Two meta-analyses investigated the outcomes of NAC 
but reported contradictory findings [10,11]. In our institution, PDS has been the standard 
treatment strategy for patients with advanced-stage ovarian cancer. In addition, NAC 
has been used for patients who were considered unsuitable for optimal PDS or who had 
significant medical comorbidities.
The European Organization for Research and Treatment of Cancer (EORTC) trial [6] 
demonstrated that survival outcomes after NAC were comparable to those of PDS. The 
median progression-free survival (PFS) was 12 months for both the PDS and NAC groups, 
whereas median overall survival (OS) was 29 and 30 months for the PDS and NAC groups, 
respectively. Importantly, the NAC group had higher rates of complete gross resection and 
lower rates of major postoperative complications. Since the publication of the EORTC 55971 
trial outcomes, our institution increased the utilization of NAC in patients with advanced-
stage ovarian cancer, fallopian tube cancers, or primary peritoneal carcinomas.
The purpose of the present study was to compare the survival outcomes before and after the 
increased adoption of NAC in our center's practice of treating advanced-stage ovarian cancer. 
We hypothesized that this paradigm shift would lead to an increased rate of no gross residual 
disease without increasing the rates of major perioperative complications.
MATERIALS AND METHODS
1. Study population
We performed a retrospective review of the medical records of patients with pathology-
confirmed International Federation of Gynecology and Obstetrics (FIGO) stage III or IV 
ovarian cancer treated at Yonsei Cancer Hospital, who received PDS or NAC between 2006 
and 2014. The following patients were excluded: patients who did not undergo PDS or IDS 
after NAC (n=9); patients lost to follow-up (n=21); patients whose medical records were not 
available (n=12). The final study population comprised 435 patients.
NAC has been used in our institution since late 2010. Therefore, we stratified the patients 
into 2 groups according to the period in which they were treated. Group 1 (control group) 
consisted of 216 patients who had been diagnosed between January 1, 2006 and December 
31, 2010; most patients in this group underwent PDS. Group 2 (study group) consisted of 219 
patients who were diagnosed between January 1, 2011 and December 31, 2014, during which 
2/10https://ejgo.org https://doi.org/10.3802/jgo.2018.29.e63
Neoadjuvant chemotherapy and ovarian cancer
time our center had adopted increased utilization of NAC for advanced-stage ovarian cancer, 
fallopian tube cancer, and primary peritoneal carcinomas.
The diagnosis was established based on open surgery, laparoscopic, or imaging-biopsy 
samples or based on fine-needle aspiration samples obtained from the tumor site or 
ascites/effusion. All surgical procedures were performed by one of the 5 gynecologic 
oncology surgeons at our institute. The histological diagnoses were based on World 
Health Organization criteria, and all microscope slides were reviewed by 2 experienced 
gynecologic pathologists. NAC was performed if at least one of the following 3 criteria 
was met: 1) presence of pulmonary and/or hepatic parenchymal metastases on imaging 
studies before surgery; 2) medically inoperable cancer; and/or 3) optimal cytoreduction 
infeasible because of high tumor burden (Fagotti score ≥8) as observed on diagnostic 
laparoscopy [12,13]. Standard surgical procedures included the following: sampling of 
free fluid or peritoneal washings for cytology; thorough inspection of the abdomen and 
pelvis, including the upper abdominal viscera, diaphragm, and retroperitoneal spaces; and 
hysterectomy, bilateral oophorectomy and omentectomy, pelvic/para-aortic lymph node 
dissection, and appendectomy. Radical surgery included bowel resection, diaphragm or 
other peritoneal surface stripping, splenectomy, partial hepatectomy, partial gastrectomy, 
or partial cystectomy with or without ureteroneocystostomy, cholecystectomy, and/or 
distal pancreatectomy [14-16]. Surgical complexity was classified, per previously published 
protocols, as low, intermediate, or high [17]. A different score was assigned to each surgical 
procedure ranging from 1 to 3 according to the complexity of the procedure. The surgical 
procedure assigned to 1 are hysterectomy, bilateral salpingo-oophorectomy, omentectomy, 
pelvic lymphadenectomy, para-aortic lymphadenectomy, abdominal peritoneum stripping, 
small bowel resection, small bowel resection, 2 are large bowel resection, diaphragm 
stripping/resection, splenectomy, liver resection, and 3 is recto-sigmoidectomy with 
anastomosis. Perioperative complications were graded using the Memorial Sloan-
Kettering Cancer Center's (MSKCC) surgical secondary events grading system [18]. Major 
complications were defined as events with MSKCC grade ≥3. Perioperative morbidity was 
defined as any adverse events (AEs) related to treatment occurring within 30 days of surgery. 
Operative mortality was defined as death occurring within 30 days after surgery (MSKCC 
grade 5). The present study was reviewed and approved by the Institutional Review Board of 
Yonsei Cancer Hospital (registration number: 4-2017-0998).
2. Statistical analysis
SPSS statistical software (version 21.0; IBM Corp., Armonk, NY, USA) was used for 
the statistical analyses. Descriptive statistics were used for demographic data and are 
summarized as the median (range) or frequency (percentage). Differences in the patient 
characteristics associated with the 2-time intervals were assessed using the χ2 or Mann-
Whitney U test. The study endpoints included PFS and OS. PFS was defined as the interval 
between the date of diagnosis and the date of the first recurrence. OS was defined as the 
interval between the date of diagnosis and the date of death. The date of recurrence was 
defined as the date of disease detection via radiology during follow-up. An increase in cancer 
antigen 125 (CA-125) levels without clinical signs of relapse was not regarded as progression 
but commonly necessitated radiological examinations. PFS and OS were analyzed using the 
Kaplan-Meier method and log-rank test. Factors identified as significant in the univariate 
analyses were entered into multivariate analysis. Cox regression analysis was used to evaluate 
the effects of the prognostic factors, expressed as hazard ratios (HRs) with 95% confidence 
intervals (CIs). For all analyses, p<0.05 was considered to indicate statistical significance.
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RESULTS
A total of 435 consecutive patients undergoing PDS or NAC at our institution were evaluated 
over the study period. A comparison of patient and clinical characteristics between group 
1 and group 2 is shown in Table 1. There were no significant between-group differences in 
patient characteristics such as age, body mass index, tumor grade, or histologic type. The 
distribution of FIGO stages was significantly different between the 2 groups: group 1, 64 
(29.6%) stage IV patients; group 2, 126 (57.5%) stage IV patients (p<0.001). Performance 
status was also different between the 2 groups, with 2.3% and 19.7% of patients having 
American Society of Anesthesiologists (ASA) score ≥3 in groups 1 and 2, respectively 
(p<0.001). The median CA-125 level was significantly different between the 2 groups: group 
1, 897.1 U/mL (range, 8.7–30,008.8); group 2, 1,474.1 U/mL (range, 12.9–30,000.0; p=0.003).
Among the entire cohort, 142 of 435 patients (32.6%) received NAC and 293 of 435 patients 
(67.4%) underwent PDS. In groups 1 and 2, 16.2% and 48.9% of patients, respectively, 
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Table 1. Patient and clinical characteristics
Characteristics Group 1 (n=216) Group 2 (n=219) p
Age (yr) 56 (22–83) 55 (26–79) 0.779
BMI (kg/m2) 22.9 (16.0–40.3) 22.5 (16.4–34.4) 0.530
FIGO stage <0.001
III 152 (70.4) 93 (42.5)
IV 64 (29.6) 126 (57.5)
Tumor grade 0.214
1 16 (7.4) 11 (5.0)
2 72 (33.4) 62 (28.3)
3 107 (49.5) 113 (51.6)
Not available 21 (9.7) 33 (15.1)
Histologic type 0.696
Serous 174 (80.6) 179 (82.1)
Endometrioid 10 (4.6) 5 (2.3)
Mucinous 14 (6.5) 14 (6.4)
Clear cell 9 (4.2) 12 (5.5)
Other 9 (4.2) 9 (3.7)
ASA score <0.001
1 128 (59.3) 60 (27.4)
2 77 (35.6) 110 (50.2)
3 5 (2.3) 42 (19.2)
4 0 (0) 1 (0.5)
Not available 6 (2.8) 6 (2.7)
Median CA-125 level (U/mL) 897.1 (8.7–30,008.8) 1,474.1 (12.9–30,000.0) 0.003
NAC <0.001
Yes 35 (16.2) 107 (48.9)
No 181 (83.8) 112 (51.1)
Chemotherapy regimen 0.006
Paclitaxel+carboplatin 156 (72.2) 171 (78.1)
Docetaxel+carboplatin 25 (11.6) 36 (16.4)
Paclitaxel+carboplatin+bevacizumab 1 (0.5) 3 (1.4)
Paclitaxel+cisplatin 2 (0.9) 3 (1.4)
IP chemotherapy 28 (13.0) 0 (0)
Others 2 (0.9) 2 (0.9)
Not available 2 (0.9) 4 (1.8)
Cycles of total chemotherapy 0.005
≤6 158 (73.1) 132 (60.3)
>6 58 (26.9) 87 (39.7)
Values are presented as median (range) or number (%).
ASA, American Society of Anesthesiologists; BMI, body mass index; CA-125, cancer antigen 125; FIGO, International Federation of Gynecology and Obstetrics; IP, 
intraperitoneal; NAC, neoadjuvant chemotherapy.
underwent NAC (p<0.001). The change in NAC use between 2006 and 2014 is shown in 
Fig. 1. Regarding the chemotherapy regimen, the use of intraperitoneal (IP) chemotherapy 
was different between the 2 groups (13.0% vs. 0%, p=0.006). The median number of 
chemotherapy cycles was 6 (range, 1–12 cycles) in both groups. In groups 1 and 2, 58 (26.9%) 
and 87 (39.7%) patients, respectively, received more than 6 cycles of chemotherapy, with a 
significant difference between the 2 groups (p=0.005). Across the study period, the rate of 
no-gross residual disease increased from 10.2% to 21.5% (p<0.001). This was followed by an 
increase in the rate of radical surgery from 35.6% in group 1 to 57.5% in group 2 (p<0.001). 
Surgical complexity was also higher in group 2 (high-surgical complexity in 3.7% and 12.8% 
of patients from groups 1 and 2, respectively; p=0.002). There were 2 (3.7%) and 1 (0.5%) 
30-day postoperative deaths (grade 5 events) in groups 1 and 2, respectively. There were 10 
(4.7%) and 13 (6.0%) grade 3 or 4 AEs in group 1 and 2, respectively. Major postoperative 
morbidity (restricted to grade 3–5) was not different between the 2 groups (5.6% vs. 6.4%, 
p=0.465) despite the increase in surgical complexity (Table 2).
The Kaplan-Meier curves for OS and PFS are shown in Fig. 2. The median follow-up period 
was 44.7 months in all patients. The median PFS was 17.6 and 17.0 months for groups 1 and 2, 
respectively. The median OS for group 1 was 63.3 months, while the median OS in group 2 was 
not reached. There were no differences in PFS or OS between the groups (p=0.449 and 0.952, 
respectively). We performed a subgroup analysis of patients who underwent PDS and NAC 
according to time period (Supplementary Figs. 1 and 2). There were no differences in PFS or 
OS between the 2 subgroups of patients who underwent PDS (p=0.873 and 0.624, respectively). 
Similarly, there were no differences in PFS or OS between the 2 subgroups of patients who 
underwent NAC during the study period (p=0.206 and 0.122, respectively). In addition, we 
performed subgroup analysis of residual disease (R0, R≤1.0 cm, R>1.0 cm). Median PFS and OS 
stratified by residual disease according to year are summarized in Supplementary Table 1 and 
Kaplan-Meier curves in Supplementary Figs. 3 and 4.
The results of the multivariate Cox regression analyses of PFS and OS in all patients are shown 
in Supplementary Table 2. Residual disease (HR=1.59; 95% CI=1.11–2.27) and high ASA score 
(HR=1.75; 95% CI=1.12–2.74) were independent prognostic factors associated with a higher risk 
of progression. In terms of survival, residual disease (HR=2.08; 95% CI=1.24–3.49) and high 
ASA score (HR=2.02; 95% CI=1.17–3.49) were independent prognostic factors in all patients.
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NAC incorporation in 2010














Fig. 1. Change in NAC use between 2006 and 2014. 
NAC, neoadjuvant chemotherapy; PDS, primary debulking surgery.
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Median PFS 17.6 vs. 17.0 mo
Fig. 2. Kaplan-Meier curves of PFS (A) and OS (B) according to time period (2006–2010 vs. 2011–2014). 
OS, overall survival; PFS, progression-free survival.
Table 2. Classification of postoperative outcomes according to the Memorial Sloan-Kettering Cancer Center's surgical secondary events grading system
Variables Group 1 (n=216) Group 2 (n=219) p
Complication grade* 0.068
0 102 (47.2) 130 (59.4)
1 15 (6.9) 9 (4.1)
2 79 (36.6) 62 (28.4)
3 10 (4.7) 10 (4.6)
4 0 (0) 3 (1.4)
5 2 (3.7) 1 (0.5)
Not available 8 (3.7) 4 (1.8)
Major complications 0.465
0–2 196 (90.7) 201 (91.8)
3–5 12 (5.6) 14 (6.4)
Not available 8 (3.7) 4 (1.8)
Residual disease <0.001
No gross 22 (10.2) 47 (21.5)
≤1.0 cm 94 (43.5) 111 (50.7)
>1.0 cm 52 (24.1) 13 (5.9)
Not available 48 (22.2) 48 (21.9)
PDS <0.001
No gross 16 (8.8) 17 (15.2)
≤1.0 cm 77 (42.5) 60 (53.6)
>1.0 cm 49 (27.1) 8 (7.1)
Not available 39 (21.5) 27 (24.1)
NAC 0.466
No gross 6 (17.1) 30 (28.0)
≤1.0 cm 17 (48.6) 51 (47.7)
>1.0 cm 3 (8.6) 5 (4.7)
Not available 9 (25.7) 21 (19.6)
Radical surgery† <0.001
None 139 (64.4) 93 (42.5)
Any radical surgery 77 (35.6) 126 (57.5)
Surgical complexity score groups‡ 0.002
1 1 (0.5) 0 (0)
2 207 (95.8) 191 (87.2)
3 8 (3.7) 28 (12.8)
Values are presented as number (%).
NAC, neoadjuvant chemotherapy; PDS, primary debulking surgery.
*According to the Memorial Sloan-Kettering Cancer Center's surgical secondary events grading system [16]; †Radical surgery included any of following: bowel 
surgery, cholecystectomy, diaphragm peritonectomy/resection, distal pancreatectomy video-assisted thoracoscopic surgery, splenectomy, liver resection, 
supraclavicular fossa resection, ureter resection, and others; ‡According to Aletti et al [17].
DISCUSSION
In this study, we investigated the impact of the adoption of NAC in our institution's clinical 
practice on survival outcomes of advanced-stage ovarian cancer over the period 9 years. Our 
analysis demonstrates that the overall NAC use increased from 16.2% to 48.9% between 2006 
and 2014 and that the incorporation of NAC increased the rate of complete gross resection 
in IDS without significantly increasing perioperative morbidity and mortality. There was no 
improvement in the survival rates during this 9-year period, and the results of multivariate 
analysis support our findings.
The EORTC 55971 and Chemotherapy OR Upfront Surgery (CHORUS) randomized controlled 
trials each showed similar survival rates between PDS and NAC groups but with improved 
optimal resection rates and less perioperative complications in the NAC groups, leading the 
authors to conclude that NAC is a reasonable treatment option for advanced-stage ovarian 
cancer [6,7]. However, these trials have been criticized because a high number of patients 
who received PDS had >1 cm of residual disease after surgery.
At our institution, the incorporation of NAC resulted in increased optimal cytoreduction rates 
and a similar rate of AEs despite more radical surgery. There was no significant difference in 
survival outcomes between the 2 groups, although the rate of radical surgery was typically 
higher in our institution. Various factors potentially associated with increased extent of 
debulking surgery should be considered, including NAC and extended surgery for advanced-
stage ovarian cancer. Primarily, the use of NAC has improved the cytoreduction rates achievable 
with IDS by reducing the disease burden [6,7]. Another important factor was the improvement 
of surgical skills in our institution during the study period. Specifically, we incorporated radical 
surgeries in an attempt to decrease residual disease at the time of PDS or IDS. Previous studies 
reported that radical surgery resulted in higher rates of complete gross resection and optimal 
resection (residual disease ≤1 cm) in advanced ovarian cancer [15,19,20]. At our institution, the 
rate of radical surgery increased from 35.6% in group 1 patients to 57.5% in group 2 patients. 
MSKCC reported a rate of 38% for extensive upper abdominal procedures in PDS, which is 
not superior to the rate of radical surgery at our institution. It is noteworthy that the complete 
resection rates also increased from 10.2% in group 1 to 21.5% in group 2. However, the 
perioperative complication rate did not differ between the 2 groups even after the incorporation 
of NAC. These findings are in contrast to the results of previous studies of NAC [6-8]. Fagotti et 
al. [8] showed that perioperative morbidity rates were more favorable for NAC than for PDS in 
advanced-stage ovarian cancer patients. Vergote et al. [6] and Kehoe et al. [7] demonstrated less 
treatment-related perioperative morbidity and mortality in NAC-treated patients than in those 
who received PDS. However, these studies did not report improvement in surgical methods 
during the study period. At our institution, the rate of radical surgery increased during the study 
period, which may have affected the rate and nature of perioperative complications. Radical 
debulking procedures required for optimal cytoreduction are often associated with significant 
morbidity and mortality [15,19].
The survival outcomes in our study were similar to those reported from the EORTC and 
CHORUS trials. The median PFS and OS for patients who underwent PDS were 17.7 and 50.5 
months, respectively, in our study, compared with 12 and 29 months, respectively, in the EORTC 
trial and 10.7 and 22.6 months, respectively, in the CHORUS trial. In the subgroup analysis, 
we found no difference in survival outcomes between groups 1 and 2 for the patients who 
underwent PDS and NAC following IDS. These findings suggest that the improvement in surgical 
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methods did affect survival outcome in this study, which is in agreement with the findings of 
the EORTC and CHORUS trials. The 2 groups in the present study received almost the same 
chemotherapy regimens. Basically, primary combination taxane and platinum-based treatment 
was administered in both groups and may have contributed to the similar survival outcomes.
One limitation of the present study is the retrospective nature of data collection. Moreover, 
we included patients who received IP chemotherapy. This is important when considering 
why survival outcomes did not appear substantially different across the time periods. Several 
studies showed that IP chemotherapy improved survival outcomes [21-23]. Suidan et al. 
[24] compared patients receiving primary intravenous (IV)/IP chemotherapy after PDS with 
those receiving consolidation IV/IP chemotherapy after PDS. Their results revealed improved 
OS in the primary IV/IP chemotherapy group (78.8 vs. 57.5 months for consolidation 
chemotherapy). Considering these data, it is possible that IP chemotherapy could have 
impacted survival outcomes in 13% of patients in group 1.
Our analysis demonstrates that the incorporation of NAC did not affect survival (PFS or OS) 
or perioperative morbidity and mortality after PDS, but was associated with increased rates of 
no-gross residual disease. The similar rates of perioperative morbidity and mortality despite 
more radical surgery and the higher rate of complete resection to no-residual disease suggest 
that NAC followed by IDS may be important for patients with advanced ovarian cancer. 
Further studies should evaluate the outcomes of patients treated with NAC in high-volume 
centers with experience in PDS. Comparative effectiveness research is required to clarify the 
effects of a paradigm shift toward widespread use of NAC.
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